What was the primary driver for the significant increase in net income in the first quarter of 2006?

The primary driver for the significant increase in net income was the recognition of substantial tax benefits. This included a $441 million benefit from the resolution of a tax matter related to Warner-Lambert Company and a $217 million benefit related to new IRS regulations on Statutory Mergers and Consolidations. These benefits, combined with a lower effective tax rate, significantly boosted profitability compared to the prior year.

How is Pfizer addressing the impact of patent expirations on its revenue?

Pfizer is addressing the impact of patent expirations through a multi-pronged strategy. This includes highlighting the proven safety and efficacy of its existing portfolio, emphasizing new clinical data to differentiate its products, investing in promising new medicines in its pipeline, and launching new products. The company also anticipates revenue growth from key products like Lipitor, Celebrex, Lyrica, and Geodon to offset declines from products losing exclusivity.

What is the 'Adapting to Scale' (AtS) initiative, and what impact is it having on Pfizer's financials?

The 'Adapting to Scale' (AtS) initiative is a multi-year productivity program launched in early 2005 designed to increase efficiency and streamline decision-making across Pfizer. It is generating significant cost savings, with at least $2 billion expected in 2006, contributing to reductions in cost of sales, selling, informational and administrative expenses, and R&D expenses. The initiative involves reorganizing R&D, optimizing manufacturing facilities, realigning marketing teams, and reducing IT and procurement costs.

What was the impact of the Exubera acquisition on Pfizer's balance sheet?

The acquisition of worldwide rights to Exubera in February 2006 for approximately $1.4 billion resulted in the recording of significant intangible assets and goodwill. Specifically, an intangible asset for developed technology rights of approximately $1.0 billion, inventory valued at $218 million, and goodwill of approximately $166 million were recorded. These were allocated to the Human Health segment.

PFE 10-Q Quarterly Report Q2 FY2006 — Revenue, Net Income, EPS

Summary

Pfizer Inc. reported a significant increase in net income for the first quarter of 2006 compared to the same period in 2005, driven by substantial tax benefits resulting from the resolution of tax matters and changes in IRS regulations. While total revenues saw a slight decrease of 3%, primarily due to patent expirations of key products and competitive pressures, the company's strategic initiatives like 'Adapting to Scale' are showing progress in cost savings. The acquisition of worldwide rights to Exubera for diabetes treatment was a notable event in the quarter. Despite the revenue headwinds from patent expiries, Pfizer's diversified product portfolio, including strong performance from certain key drugs like Lipitor, Celebrex, Lyrica, and Geodon, is expected to partially offset these declines. The company is actively managing its cost structure through its productivity initiatives and is investing in its pipeline for future growth. Investors should monitor the impact of upcoming patent expiries and the success of new product launches.

Key Highlights

1Net income surged to $4.11 billion in Q1 2006 from $301 million in Q1 2005, largely due to significant tax benefits from tax resolutions and regulatory changes.
2Total revenues decreased by 3% to $12.66 billion in Q1 2006, primarily impacted by the loss of exclusivity for major products like Zithromax, Neurontin, Diflucan, and Accupril/Accuretic.
3The company acquired worldwide rights to Exubera, an inhaled insulin for diabetes, for approximately $1.4 billion, recording significant intangible assets and goodwill.
4Pfizer's 'Adapting to Scale' (AtS) productivity initiative is progressing, with expected cost savings of at least $2 billion in 2006, contributing to reduced Cost of Sales, Selling, Informational and Administrative expenses, and R&D expenses.
5Despite revenue challenges from patent expiries, key products like Lipitor, Celebrex, Lyrica, and Geodon showed solid performance, with Lyrica and Geodon experiencing strong growth.
6The company's effective tax rate decreased dramatically to 7.1% in Q1 2006 from 90.6% in Q1 2005, due to tax benefits and regulatory adjustments.
7Pfizer is exploring strategic options for its Consumer Healthcare business, including a possible sale or spin-off, with a decision expected by the end of Q3 2006.

PFIZER INC Quarterly Report for Q2 Ended Apr 2, 2006

Summary

Key Highlights

Frequently Asked Questions